Quarterly ResultMay 14, 2026, 04:23 PM
Cue Biopharma Q1 Net Loss $(5.178)M; Collaboration Revenue Up
AI Summary
Cue Biopharma reported a reduced net loss of $(5.178) million for the first quarter of 2026, a significant improvement from $(12.257) million in the prior year, driven by a substantial increase in collaboration revenue to $5.686 million. Despite this, the company's recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern. However, Cue Biopharma subsequently secured $27.6 million in net proceeds from a private placement in May 2026 to support future operations.
Key Highlights
- Net loss for Q1 2026 was $(5.178) million, an improvement from $(12.257) million in Q1 2025.
- Collaboration revenue increased significantly to $5.686 million in Q1 2026 from $0.421 million in Q1 2025.
- Research and development expenses decreased to $6.897 million in Q1 2026 from $8.547 million in Q1 2025.
- General and administrative expenses were $4.152 million in Q1 2026, slightly down from $4.173 million in Q1 2025.
- Cash and cash equivalents were $16.379 million as of March 31, 2026, down from $27.136 million at December 31, 2025.
- Net loss per common share was $(1.08) in Q1 2026, compared to $(4.95) in Q1 2025.
- Company received $27.6 million in net proceeds from a private placement in May 2026.
- The company's recurring losses raise substantial doubt about its ability to continue as a going concern.